Metraipolis › archive › dc_6bbae1c8a682

Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency — Europe PMC PMID:42819971

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42819971
DOI: 10.1093/jbmrpl/ziag151
License (as archived): solo-consultazione
Archived: 2026-10-10T01:31:59.755Z
SHA-256 of the archived text: b6f27d657f4001d228b5bf5569c977532d3b1d27a7d65567e441c3e15f95aac5
Stable URL of this page: https://metraipolis.com/documento/dc_6bbae1c8a682

How to cite

Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency — Europe PMC PMID:42819971 — Europe PMC (en), https://europepmc.org/article/MED/42819971 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6bbae1c8a682 (Metraipolis archive dc_6bbae1c8a682, sha256 b6f27d657f4001d228b5bf5569c977532d3b1d27a7d65567e441c3e15f95aac5)

BibTeX

@misc{dc6bbae1c8a682,
  title = {Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency — Europe PMC PMID:42819971},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42819971},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6bbae1c8a682; sha256 b6f27d657f4001d228b5bf5569c977532d3b1d27a7d65567e441c3e15f95aac5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42819971. Agents can read the archived copy with the MCP tool read_document.